BACKGROUND: For women at potentially increased risk for ovarian cancer, data regarding screening and risk reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about the behaviors of non- BRCA carriers. We surveyed a large cohort of women after BRCA testing to identify the prevalence and posttest predictors of risk-reducing and screening interventions. METHODS: A median of 3.7 years after BRCA testing, 1447 women who received genetic counseling and BRCA testing at 2 hospital sites were surveyed, with a 77.6% response rate. We analyzed data from 1077 survey respondents. We performed univariate and multivariate logistic regression analyses to identify predictors of risk-reducing salpingo-oophorectomy (RRSO), screening transvaginal ultrasonography (TVUS), and screening serum cancer antigen 125 (CA-125). RESULTS: Among the respondents, 201 women (18.7%) received positive test results for a deleterious mutation, 103 women (9.6%) received true-negative results, and 773 women (71.8%) received uninformative results. Overall, 19.1% of eligible women underwent RRSO and 39.6% used screening procedures. A positive BRCA result predicted RRSO (odds ratio [OR], 28.1; 95% CI, 16.2-48.6), TVUS (9.5 [4.3-21.0]), and serum CA-125 (13.0 [5.5-29.0]). Similarly, a true-negative BRCA result reduced the OR for RRSO (0.1 [0.0-0.6]), TVUS (0.2 [0.1-0.5]), and serum CA-125 (0.3 [0.1-0.7]). Of the 71.8% of women who received uninformative results after BRCA testing, 12.3% subsequently underwent RRSO, 33.8% reported ever having undergone screening serum CA-125 since BRCA testing, and 37.3% reported ever having undergone screening TVUS since BRCA testing. CONCLUSIONS: Results of BRCA testing strongly predict RRSO and ovarian cancer screening. Use of RRSO and ovarian screening was reported in a sizable percentage of non- BRCA carriers despite insufficient data to determine the effectiveness of these interventions.
BACKGROUND: For women at potentially increased risk for ovarian cancer, data regarding screening and risk reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about the behaviors of non- BRCA carriers. We surveyed a large cohort of women after BRCA testing to identify the prevalence and posttest predictors of risk-reducing and screening interventions. METHODS: A median of 3.7 years after BRCA testing, 1447 women who received genetic counseling and BRCA testing at 2 hospital sites were surveyed, with a 77.6% response rate. We analyzed data from 1077 survey respondents. We performed univariate and multivariate logistic regression analyses to identify predictors of risk-reducing salpingo-oophorectomy (RRSO), screening transvaginal ultrasonography (TVUS), and screening serum cancer antigen 125 (CA-125). RESULTS: Among the respondents, 201 women (18.7%) received positive test results for a deleterious mutation, 103 women (9.6%) received true-negative results, and 773 women (71.8%) received uninformative results. Overall, 19.1% of eligible women underwent RRSO and 39.6% used screening procedures. A positive BRCA result predicted RRSO (odds ratio [OR], 28.1; 95% CI, 16.2-48.6), TVUS (9.5 [4.3-21.0]), and serum CA-125 (13.0 [5.5-29.0]). Similarly, a true-negative BRCA result reduced the OR for RRSO (0.1 [0.0-0.6]), TVUS (0.2 [0.1-0.5]), and serum CA-125 (0.3 [0.1-0.7]). Of the 71.8% of women who received uninformative results after BRCA testing, 12.3% subsequently underwent RRSO, 33.8% reported ever having undergone screening serum CA-125 since BRCA testing, and 37.3% reported ever having undergone screening TVUS since BRCA testing. CONCLUSIONS: Results of BRCA testing strongly predict RRSO and ovarian cancer screening. Use of RRSO and ovarian screening was reported in a sizable percentage of non- BRCA carriers despite insufficient data to determine the effectiveness of these interventions.
Authors: Robin Lee; Mary Beattie; Beth Crawford; Julie Mak; Nicola Stewart; Miriam Komaromy; Laura Esserman; Lucille Shaw; Jane McLennan; Lori Strachowski; Judy Luce; John Ziegler Journal: Genet Test Date: 2005
Authors: Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck Journal: JAMA Date: 2010-09-01 Impact factor: 56.272
Authors: Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: Joanna B Madalinska; Marc van Beurden; Eveline M A Bleiker; Heiddis B Valdimarsdottir; Lottie Lubsen-Brandsma; Leon F Massuger; Marian J E Mourits; Katja N Gaarenstroom; Eleonora B L van Dorst; Hans van der Putten; Henk Boonstra; Neil K Aaronson Journal: J Clin Oncol Date: 2007-01-20 Impact factor: 44.544
Authors: Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod Journal: Int J Cancer Date: 2008-05-01 Impact factor: 7.396
Authors: B B J Hermsen; R I Olivier; R H M Verheijen; M van Beurden; J A de Hullu; L F Massuger; C W Burger; C T Brekelmans; M J Mourits; G H de Bock; K N Gaarenstroom; H H van Boven; T M Mooij; M A Rookus Journal: Br J Cancer Date: 2007-04-10 Impact factor: 7.640
Authors: Xinglei Chai; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Peter J Hulick; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joanne L Blum; Susan M Domchek; Jinbo Chen; Timothy R Rebbeck Journal: Breast Cancer Res Treat Date: 2014-10-14 Impact factor: 4.872
Authors: Kimberly M Kelly; Lee Ellington; Nancy Schoenberg; Thomas Jackson; Stephanie Dickinson; Kyle Porter; Howard Leventhal; Michael Andrykowski Journal: J Behav Med Date: 2014-12-23
Authors: Charles W Drescher; J David Beatty; Robert Resta; M Robyn Andersen; Kate Watabayashi; Jason Thorpe; Sarah Hawley; Hannah Purkey; Jessica Chubak; Nancy Hanson; Diana S M Buist; Nicole Urban Journal: Cancer Date: 2016-07-22 Impact factor: 6.860
Authors: Lieske H Schrijver; Håkan Olsson; Kelly-Anne Phillips; Mary Beth Terry; David E Goldgar; Karin Kast; Christoph Engel; Thea M Mooij; Julian Adlard; Daniel Barrowdale; Rosemarie Davidson; Ros Eeles; Steve Ellis; D Gareth Evans; Debra Frost; Louise Izatt; Mary E Porteous; Lucy E Side; Lisa Walker; Pascaline Berthet; Valérie Bonadona; Dominique Leroux; Emmanuelle Mouret-Fourme; Laurence Venat-Bouvet; Saundra S Buys; Melissa C Southey; Esther M John; Wendy K Chung; Mary B Daly; Anita Bane; Christi J van Asperen; Encarna B Gómez Garcia; Marian J E Mourits; Theo A M van Os; Marie-José Roos-Blom; Michael L Friedlander; Sue-Anne McLachlan; Christian F Singer; Yen Y Tan; Lenka Foretova; Marie Navratilova; Anne-Marie Gerdes; Trinidad Caldes; Jacques Simard; Edith Olah; Anna Jakubowska; Brita Arver; Ana Osorio; Catherine Noguès; Nadine Andrieu; Douglas F Easton; Flora E van Leeuwen; John L Hopper; Roger L Milne; Antonis C Antoniou; Matti A Rookus Journal: JNCI Cancer Spectr Date: 2018-06-28
Authors: Daphne Gschwantler-Kaulich; Sigrid Weingartshofer; Christine Rappaport-Fürhauser; Robert Zeillinger; Dietmar Pils; Daniela Muhr; Elena I Braicu; Marie-Therese Kastner; Yen Y Tan; Lorenz Semmler; Jalid Sehouli; Christian F Singer Journal: PLoS One Date: 2017-12-15 Impact factor: 3.240
Authors: Fahima Dossa; Maria C Cusimano; Rinku Sutradhar; Kelly Metcalfe; Tari Little; Jordan Lerner-Ellis; Andrea Eisen; Wendy S Meschino; Nancy N Baxter Journal: BMJ Open Date: 2018-09-04 Impact factor: 2.692